5.38k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track stocks that have been oversold as indicated by the RSI momentum indicator within the last week. A stock is oversold when the RSI is below 30. This list is generated daily, ranked based on market cap and limited to the top 30 stocks that meet the criteria.
Based on Friday’s price action and the close at 97.530, the direction of the September U.S. Dollar Index on Monday is likely to be determined by trader reaction to the support cluster at 97.545 to 97.510.
The Canadian Dollar rose 0.15% against the U.S. Dollar. Gains were limited by a steep drop in crude oil prices. The Euro posted a 0.46% gain against the dollar, but due to its heavy weighting, it had the biggest influence on the index’s decline.
The British pound initially fell during the week but then rallied towards the crucial 1.2250 level again. This is an area that has been important more than once, so it makes sense that we are struggling just a bit here. That being said though, I think that the market is simply bouncing from a very low level.
The British pound has gone back and forth during trading on Friday, as we continue to see a lot of volatility in Sterling. Quite frankly, there is nothing on the horizon that looks like the Brexit is going to be salt, so this should offer a nice selling opportunity at higher levels.
Raytheon's (RTN) ESSM program provides self-defense battle space and firepower against high-speed anti-ship missiles in the naval environment including aircraft, high and low velocity air threats.
FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.
Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.
After a sharp move higher yesterday on the back of positive Brexit comments, the British pound has eased lower in early trading on Friday.
The transport and logistics firm is reviewing its accounting, suspending trading until it can reveal a likely downgrade to its earnings.
GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business. Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion last year and an agreement in February to pay up to 3.7 billion euros ($4.09 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.
Boris Johnson returns and having failed to fully push the door open to renegotiations could be in for a tough week ahead…